Background-A need exists to expand the characterization of tetrahydrobiopterin (BH 4 ) responsiveness in patients with phenylketonuria (PKU), beyond simply evaluating change in blood phenylalanine concentrations. The clinical interpretation of BH 4 responsiveness should be evaluated within the context of phenylalanine hydroxylase (PAH) genotype.
Introduction
Phenylalanine hydroxylase (PAH; EC 1.14.16.1) genotype is playing an increasingly important role in the management of patients with phenylketonuria (PKU; OMIM 261600), especially with the emergence of tetrahydrobiopterin (BH 4 ) therapy. Found to lower blood phenylalanine concentrations in a subset of patients with PKU [1] , BH 4 is believed to improve the activity of certain dysfunctional PAH enzymes by optimizing cellular BH 4 concentrations, acting as a pharmacological chaperone, and/or overcoming kinetic variants [2] [3] [4] . BH 4 's modes of action are contingent on the enzymes produced from the mutated gene. As such, PAH genotype should play a pivotal role in defining BH 4 responsiveness.
PAH genotype is currently not a standard criterion for BH 4 response classification. Patients are typically categorized as either "responders" or "non-responders" based only on percent change in blood phenylalanine concentrations after being administered BH 4 [5, 6] . Protocols assessing responsiveness are highly divergent with respect to variables that can affect circulating phenylalanine concentrations, such as diet prescription compliance, length of evaluation, dose of BH 4 , and use of a pre-BH 4 phenylalanine load [6, 7] . Not surprisingly, inconsistencies in the relationship between PAH genotype and response classification have emerged [6, 8, 9] . Discordant categorization is rarely attributed to response misclassification, despite some "responsive" patients having severe PAH genotypes [10, 11] or limited to no long-term clinical benefits with continued use [12] [13] [14] [15] [16] [17] . Thus, a need exists to expand the scope of BH 4 response classification.
We recently described a novel clinical algorithm for assessing BH 4 responsiveness which includes both change in plasma phenylalanine concentrations and ability to modify dietary restrictions as criteria [18] . This approach allowed us to identify a subgroup of patients which experienced an initial marked decrease in plasma phenylalanine concentrations, but had only marginal improvements in dietary phenylalanine tolerance. Similar patients have been reported in protocols different from ours [13, 14] . It is unclear if these patients represent a truly responsive group or are merely artifacts of the protocols assessing responsiveness. PAH genotype may help to shed light on the nature of this subgroup.
From a clinical perspective, PAH genotypes are often difficult to interpret. The severity of a mutation or genotype can be explored through open-access databases like the Phenylalanine HydroxylaseLocus Knowledgebase ( [19] . While not intended for BH 4 response classification, this tool may serve as a starting point for incorporating PAH genotype into the clinical definition of BH 4 responsiveness. The goals of this investigation are to use this tool to assess the molecular basis of responsiveness in our clinical cohort and to explore the utility of using a genotype severity tool to differentiate BH 4 responsive groups.
Patients and methods

Patients and clinical BH 4 response classification
Patients at least 4 years of age, diagnosed PAH-deficient hyper-phenylalaninemia were enrolled in a single-center, clinical trial assessing BH 4 responsiveness. Response was classified using a multi-criteria approach outlined in Table 1 and detailed elsewhere [18] . Briefly, patients were first categorized based on change in plasma phenylalanine concentrations after one month of 20 mg/kg/day BH 4 therapy (sapropterin dihydrochloride; Kuvan®, BioMarin Pharmaceutical Inc., Novato, CA). Patients with ≥15% decrease in plasma phenylalanine concentrations continued BH 4 therapy and were further segregated based on subsequent ability to increase dietary phenylalanine tolerance and decrease medical food needs while maintaining plasma phenylalanine concentrations ≤360 μmol/L. Three BH 4 response groups emerged: definitive responders, provisional responders, and nonresponders. Provisional responders represent a clinically ambiguous group, experiencing an initial decrease in plasma phenylalanine concentrations but being unable to substantially change their dietary phenylalanine tolerance or medical food needs. Noncompliant patients or those lost to follow-up remain unclassified. Informed consent was received for all patients. This study was approved by the Emory University Institutional Review Board.
PAH mutation identification
PAH genotypes were assessed retrospectively, and were not evaluated as part of the clinical BH 4 response classification. When available, PAH genotypes were taken from participants' medical records. These PAH mutations were identified using polymerase chain reaction and DNA sequencing of the 13 coding exons and flanking regions. If only one mutation was identified, a second sample was analyzed using a PAH gene-specific comparative genomic hybridization array [20] . For patient who had not been clinically genotyped, a filter paper blood spot was collected which provided DNA that was analyzed using high-resolution melt profiling, as previously described [21] . Mutations were characterized by location (i.e. exon, intron, untranslated region) and by type (missense, mRNA processing, nonsense, or deletion).
Assessing PAH genotype severity using assigned value (AV) sum
PAH genotype severity was assessed using the assigned valued (AV) sum approach developed by Guldberg et al. [19] . The method was created by evaluating nearly 300 functionally hemizygous patients with PKU and using the patients' phenotypic severity to classifying a total of 105 different mutations. Each mutation was given an AV of 1, 2, 4, or 8. A lower mutation AV corresponds to a more severe phenotype. Mutations with an AV of 1 are considered particularly severe in nature, with many classified as putative null mutations. Mutations with AV>1 are associated with moderate or mild phenotypes, suggesting that the mutation retains some functionality. To assess the severity of a patient's genotype, both mutations' AVs are added together (the "AV sum"). AV sums range from 2 to 16, again with a lower number indicating a more severe phenotype.
Some minor modifications to the AV sum approach were necessary for our analysis. First, there were certain mutations which had been assigned to multiple AVs due to a wide range of clinical phenotypes observed in the original analysis. In those instances, we only used the mutation AV most frequently designated by Guldberg et al. (see Appendix in Ref. [19] ). To expand our ability to give a patient an AV sum, decidedly severe mutations not previously evaluated in the AV sum analysis-such as large deletions, frame shift mutations, and disruptions of canonical splice site motifs-were given a mutation AV of 1. Finally, since not all mutations identified in our clinic population had a designated mutation AV, some patients were given an "indefinite AV sum" (e.g. ≥2, ≥3, ≥4, etc). The indefinite AV sum is, at minimum, one greater than the AV for the characterized mutation.
Assessment of classification approaches and statistics
The ability of the AV sum to differentiate the clinically designated BH 4 responses and the genetic basis of responsiveness were simultaneously assessed, as outlined in Fig. 1 . Patients were first dichotomized into "true responder" and "true non-responder" groups based on the clinical response classification described in Section 2.1 and Table 1 . Due to the clinical ambiguity of the provisional responder group, two iterations were evaluated: (1) provisional responders were classified with the definitive responders in a single "true responder" group and (2) provisional responders were classified with the non-responders in a single "true nonresponder" group. Patients were then classified by their AV sum. Patients with an AV sum>2 were classified "AV sum responders" those with an AV sum=2 were classified as "AV sum non-responders." This threshold was selected, as an AV sum of 2 represents a severe genotype with limited to no molecular basis for responsiveness. Patients with the indefinite AV sum of ≥2 were obligate "AV sum non-responders," since an AV sum above 2 could not definitively be assigned. Since obligate AV sum non-responders have the potential to bias the analysis, results are presented both with and without these patients. To quantify the ability of AV sum to classify BH 4 response, sensitivity, specificity, positive predictive value, and negative predictive value were calculated. Patients with an unclassified BH 4 response, while presented in the descriptive and summary statistics, were excluded from this portion of the analysis.
Results
Summary of identified mutations
A total of 58 patients were genotyped: 19 definitive responders, 9 provisional responders, 25 non-responders, and 5 unclassified patients. Of the expected 116 alleles, 114 mutations were identified (98.3% detection rate). In two patients, only one mutation could be identified, although their clinical and biochemical profiles indicated PAH-deficient hyperphenylalaninemia. There were 47 different mutations identified within our clinical cohort. Mutations affected all 13 exons, 7 introns (intron 1, 4, 5, 6, 8, 10 and 12), and the 3′ untranslated region. As Table 2 shows, missense mutations comprise the majority of the 47 distinct mutations and the majority of 116 alleles. Table 3 presents the PAH genotypes and AV sums of all patients, separated into their respective BH 4 response groups. The majority of definitive responders (17/19 patients) had an AV sum>2, indicating that at least one mutation is moderate or mild in severity. The remaining two definitive responders carried a severe mutation (AV=1) in combination with an uncharacterized mutation, and were given an indefinite AV sum of ≥2. In contrast, 7/9 provisional responders had a severe PAH genotype (AV sum=2). The two remaining provisional responders had AV sums of 5.
PAH genotype AV sum by BH 4 response classification
Non-responders represented a particularly heterogeneous group. The majority of nonresponders (15/25 patients) had an AV sum of 2, indicating a severe PAH genotype. However, 5/25 non-responders had an AV sum>2, carrying a mild or moderate mutation in combination with a severe mutation. The remaining 5 non-responders had a severe mutation (AV=1) in combination with an uncharacterized mutation, and were assigned an indefinite AV sum≥2. The unclassified patients' AV sums indicate their genotypes are primarily severe. One unclassified patient, who was lost to follow-up, has an AV sum of 6.
Discordant BH 4 response classification of matching PAH genotypes
Several patients had a PAH genotype matching one or more enrolled patient, including five pairs of siblings, four pairs of unrelated patients, and one unrelated patient matching a sibling pair. Of these, two sibling sets and two unrelated sets had discordant clinical BH 4 response classification. In these four instances, one patient was classified as a non-responder and the other patient was classified as a provisional responder. The PAH genotype AV sum in each instance was 2, indicating that both mutations were severe in nature. Interestingly, none of these discordant classifications included a patient being classified as a definitive responder. Table 4 shows the ability of the AV sum to predict clinical BH 4 response classification. Categorizing provisional responders with the non-responder group improved sensitivity and negative predictive value with little detriment to specificity and positive predictive value. As expected, excluding patients with an indefinite AV sum of ≥2 improved the sensitivity of using AV sum to classify BH 4 responsiveness.
Ability of AV sum to predict BH 4 response
Discussion
PAH genotype severity has important implications for clinical classification of BH 4 responsiveness. With seven of nine of our provisional responders carrying two severe or null mutations, there is strong evidence to suggest they do not represent a truly responsive group. The discordant classification of four sets of patients with matching PAH genotypes-with one patient being classified as a non-responder and one patient being classified as a provisional responder-further suggests that the initial change in plasma phenylalanine concentrations in the provisional responders cannot necessarily be attributed to a drug effect. These findings highlight the potential for patient misclassification in extended protocols relying solely on change in plasma phenylalanine concentrations. As BH 4 response classification continues to evolve, it is essential that the definition becomes more comprehensive to encompass change in plasma phenylalanine concentrations, change in dietary phenylalanine tolerance and medical food needs, and PAH genotype. Identification of misclassified patients must also become a crucial element of BH 4 response assessment.
In our clinical cohort, one mild or moderate mutation was necessary but not sufficient for BH 4 responsiveness. In two instances, a definitive responder carried an uncharacterized mutation in combination with a severe mutation. The literature, while sparse, indicates that the uncharacterized mutation in each of these patients-p.P275S [13, 22] and p.P366H [23, 24] , respectively-does not produce a severe phenotype, even when coupled with a severe or null mutation. Thus, it appears that all of our definitive responders have an AV sum>2, including these two patients. Surprisingly, the ability of AV sum to differentiate our non-responder group is less straightforward. Assuming our clinical classification of BH 4 responsiveness is accurate, relying solely on AV sum to predict response classification led to a substantial number of false-positive cases. These genotypic inconsistencies, however, may potentially expose inherent limitations of current BH 4 response protocols, especially those spanning days or weeks. The lack of demonstrated decrease in plasma phenylalanine concentrate may have been affected by numerous factors, including: overall metabolic state of the patient, change in health status, non-compliance with BH 4 , or alteration of dietary intake [2, [25] [26] [27] . Extensive evaluation of these potentially misclassified patients may elucidate limitations of the AV sum approach or clinical BH 4 response protocols.
The concept of evaluating PAH genotype for BH 4 responsiveness is not a novel one. Efforts have been made to identify "responsive" alleles from the clinical results of various BH 4 response protocols [27, 28] . This approach, however, is limited in that it is reliant on divergent protocols which do not assess patient misclassification, and ambiguity has arisen. A simple, BH 4 -specific clinical tool has yet to be developed. In contrast, PAH genotype AV sum is an easy tool, developed independent of BH 4 response classification. While our data may be preliminary in nature, the AV sum approach appears to provide a high degree of sensitivity for identifying patients who have both biochemical and dietary benefits from BH 4 therapy. AV sum, in its current state, may serve as a tool for screening patients who should be evaluated for responsiveness. In retrospective analyses, the AV sum may help identify potentially misclassified patients.
While our data are promising, some limitations of our study should be noted. Although a group of 58 patients with PKU assessed at a single clinic is substantial, the external validity of our findings needs to be assessed. Moreover, we could not confirm that the two mutations are in trans in each patient due to incomplete parental studies. There is a potential that some patients' mutations are in cis and that these patients may harbor an additional unidentified mutation; however, these cases are relatively atypical and rare [29] . Furthermore, some adjustments to the AV sum approach should be considered before widespread implementation. For example, the mutation c.1066-3C>T is classified as a severe mutation (AV=1), but is known to maintain some normal splicing properties and can result in a mild phenotype [30, 31] . An expansion of the number of mutations with an AV score would also be necessary. The AV sum tool, should be considered a starting point for the clinical utilization of PAH genotype for response classification.
In conclusion, AV sum appears to be a useful clinical tool for identifying potential candidates for BH 4 therapy and retrospectively evaluating BH 4 response misclassification. As our provisional responder group exemplifies, a change in phenylalanine concentrations does not always indicate BH 4 responsiveness. Our findings underscore the importance of factors such as genotype and dietary phenylalanine tolerance when assessing a patient's response to BH 4 .
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Abbreviations
AV
assigned value Classification of clinical BH 4 response and assigned value (AV) sum to evaluate the utility of a PAH genotype severity tool. Table 1 Clinical BH 4 response classification of patients with PKU using a novel, multi-criteria algorithm.
Response classification
Classification criteria
Definitive responder Frequency of PAH mutation types in patients with PKU evaluated for BH 4 responsiveness (N = 58). 
